← Patent-cliff monitor small molecule RINVOQ LQ UPADACITINIB
Loss of exclusivity October 2036 latest FDA-listed patent expiry
Company AbbVie Inc. → See this company's full patent-cliff portfolio Drug detail Brand name RINVOQ LQ Active ingredient UPADACITINIB Strength 1MG/ML Dosage form SOLUTION Route ORAL Modality Small molecule FDA approval April 2024 Marketing status RX
Listed patents Patent Expires Type 11186584 October 2036 substance 11773105 October 2036 substance 12365689 October 2036 use U-3945 9951080 October 2036 substance 10981923 October 2036 substance 11680069 October 2036 substance 12110298 October 2036 substance 11718627 October 2036 substance 11661425 October 2036 substance RE47221 August 2033 substance 8962629 January 2031 substance
Regulatory exclusivity Code Expires ODE-481 April 2031 NP April 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.